6-year non-interventional multicenter safety post-authorization study conducted in patients prescribed JINARC due to autosomal dominant polycytosis of the kidney
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: OTSUKA PHARMACEUTICAL EUROPE LTD
- Execution start: 03/11/2020
- End of execution: 30/09/2029
- PI: ANA ISABEL MORALES GARCIA